Digital Therapeutics for Mental Health and Addiction
The State of the Science and Vision for the Future
- 1st Edition - September 27, 2022
- Editors: Nicholas C. Jacobson, Tobias Kowatsch, Lisa A. Marsch
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 0 4 5 - 4
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 8 5 6 1 - 4
Digital Therapeutics for Mental Health and Addiction: The State of the Science and Vision for the Future presents the foundations of digital therapeutics with a broad audience… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteDigital Therapeutics for Mental Health and Addiction: The State of the Science and Vision for the Future presents the foundations of digital therapeutics with a broad audience in mind, ranging from bioengineers and computer scientists to those in psychology, psychiatry and social work. Sections cover cutting-edge advancements in the field, offering advice on how to successfully implement digital therapeutics. Readers will find sections on evidence for direct-to-consumer standalone digital therapeutics, the efficacy of integrating digital treatments within traditional healthcare settings, and recent innovations currently transforming the field of digital therapeutics towards experiences which are more personalized, adaptable and engaging.
This book gives a view on current limitations of the technology, ideas for problem-solving the challenges of designing this technology, and a perspective on future research directions. For all readers, the content on cultural, legal and ethical dimensions of digital mental health will be useful.
- Gives a comprehensive overview of the field of digital therapeutics and research on their efficacy, effectiveness, scalability and cost-effectiveness
- Introduces novel directions in which digital therapeutics are currently being extended, including personalized interventions delivered in real-time
- Reviews important considerations surrounding digital therapeutics, including how they can be monetized and scaled, ethical issues, cultural adaptations, privacy and security concerns, and potential pitfalls
Computer scientists, data scientists and engineers who are working in the field of digital therapeutics, such as development of programs, apps, patient monitoring technology, chatbots, and voice assistants. Researchers and graduate students in the field of mental health, including psychology, counselling, psychiatry, and social work. Clinical psychology, counselling psychology, counselling, psychiatry, substance use counselling, and social work training programs are increasingly launching clinical applications of digital health , and this book might be a text that could be incorporated into mental health or digital health programs as well as their new virtual counterparts
- Cover Image
- Title Page
- Copyright
- Table of Contents
- Contributors
- Foreword
- Chapter 1 Introduction: A vision for the field of digital therapeutics
- 1.1 Why read this book?
- 1.2 Who is this book for?
- 1.3 What topics are covered in this book?
- 1.4 What will readers learn?
- Chapter 2 Using digital therapeutics to target gaps and failures in traditional mental health and addiction treatments
- 2.1 Prevalence and impact of mental health and substance use disorders
- 2.2 Lack of treatment receipt in the traditional care system
- 2.3 Barriers to traditional treatment: stigma, personal beliefs, and cultural competence
- 2.4 Barriers to traditional treatment: cultural competence
- 2.5 Barriers to traditional treatment: high cost and lack of insurance coverage
- 2.6 Barriers to traditional treatment: transportation and appointment time availability
- 2.7 Barriers to traditional treatment: inadequate number of mental health providers
- 2.8 Barriers to traditional treatment: patient narratives
- 2.9 Leveraging digital therapeutics to transform treatment models for mental health and substance use disorders
- 2.10 A time of opportunity to transform models of mental health and substance use care via digital therapeutics
- References
- Chapter 3 First wave of scalable digital therapeutics: Internet-based programs for direct-to-consumer standalone care for mental health and addiction
- 3.1 Development of internet-based programs
- 3.2 Internet-based programs for substance use disorders
- 3.3 Internet-based programs for mental health (nonsubstance related disorders)
- 3.4 Summary and next steps for internet-based programs for substance use and mental health disorders
- References
- Chapter 4 Second wave of scalable digital therapeutics: Mental health and addiction treatment apps for direct-to-consumer standalone care
- 4.1 Overview of second-wave digital therapeutics
- 4.2 Evidence base for second wave digital therapeutics
- 4.3 Cautions and limitations with second-generation digital therapeutics
- 4.4 How to find effective second-wave digital therapeutics
- 4.5 How to use second-wave digital therapeutics in practice
- 4.6 Summary and future directions
- References
- Chapter 5 Blending digital therapeutics within the healthcare system
- 5.1 Introduction
- 5.2 Blended care terminology
- 5.3 Components and structure of blended care
- 5.4 Blended care treatment approaches
- 5.5 Development and value of blended care
- 5.6 Illustrations
- 5.7 Challenges to the adoption of blended care
- 5.8 Future directions and conclusions
- References
- Chapter 6 Receptivity to mobile health interventions
- 6.1 Introduction
- 6.2 The anatomy of an “ideal” mobile health intervention
- 6.3 Key processes of receptivity: receiving, processing, and using support
- 6.4 What do we already know about states of receptivity?
- 6.5 Challenges and future work
- References
- Chapter 7 Adapting just-in-time interventions to vulnerability and receptivity: Conceptual and methodological considerations
- 7.1 Introduction
- 7.2 Just-in-time adaptive interventions
- 7.3 JITAI components
- 7.4 States of vulnerability and receptivity
- 7.5 Scientific questions about vulnerability and receptivity in just-in-time intervention development
- 7.6 Analyzing observational ILD to inform JITAI development
- 7.7 Analyzing ILD from microrandomized trials
- 7.8 Conclusion
- Acknowledgments
- References
- Chapter 8 A digital therapeutic alliance in digital mental health
- 8.1 Introduction
- 8.2 What is therapeutic alliance?
- 8.3 Applying therapeutic alliance to DMHIs: digital therapeutic alliance
- 8.4 Defining digital therapeutic alliance
- 8.5 Differences in DTA across interventions
- 8.6 DTA in supported interventions
- 8.7 DTA in unsupported interventions
- 8.8 Measurement
- 8.9 Impact
- 8.10 Improving DTA
- 8.11 The future of DTA
- 8.12 Future directions and recommendations
- 8.13 Conclusions
- References
- Chapter 9 Conversational agents on smartphones and the web
- 9.1 Introduction
- 9.2 Conversational agents on the web
- 9.3 Conversational agents on smartphones
- 9.4 Safety issues in using conversational agents
- 9.5 Future directions
- 9.6. Conclusion
- References
- Chapter 10 Voice-based conversational agents for sensing and support: Examples from academia and industry
- 10.1 Introduction
- 10.2 Method
- 10.3 Findings
- 10.4 Most prevalent features and trends
- 10.5 Conclusion and outlook
- References
- Chapter 11 Design considerations for preparation, optimization, and evaluation of digital therapeutics
- 11.1 Introduction
- 11.2 A framework for designing and evaluating digital therapeutic interventions
- 11.3 Design considerations for intervention development
- 11.4 Design considerations for short-term & long-term efficacy, effectiveness, and implementation
- 11.5 Discussion and conclusion
- References
- Chapter 12 Cultural adaptations of digital therapeutics
- 12.1 Introduction
- 12.2 Global burden of mental illness and need for cultural adaptation
- 12.3 Methods of cultural adaptation
- 12.4 Cultural adaptation of digital interventions
- 12.5 Recommendations for applying cultural adaptations to digital therapeutics
- 12.6 Conclusion
- Acknowledgments
- Declaration of Interest
- References
- Chapter 13 Building the digital therapeutic industry: Regulation, evaluation, and implementation
- 13.1 A new category of medicine
- 13.2 Digital Therapeutics Alliance
- 13.3 Industry progression
- 13.4 2017–2021: Foundation building
- 13.5 2022 & beyond: Equipping decision-makers and end-users
- 13.6 Looking ahead
- Reference
- Chapter 14 Potential pitfalls and lessons learned
- 14.1 If you build it, we will come, but we may not stay
- 14.2 The human element
- 14.3 Access does not equal uptake
- 14.4 A “lift-and-shift” approach does not work
- 14.5 A blended model of treatment is needed
- 14.6 Multidimensional, theory-informed implementation models are needed
- 14.7 A more responsive research and development cycle is needed
- 14.8 Summary
- References
- Chapter 15 Privacy and security in digital therapeutics
- 15.1 Introduction
- 15.2 Background on privacy and security in digital therapeutics
- 15.3 Relevant security and privacy regulations
- 15.4 Addressing privacy and security concerns
- 15.5 Conclusions
- References
- Chapter 16 Ethical considerations of digital therapeutics for mental health
- 16.1 Introduction
- 16.2 Ethical issues arising from digital therapeutics in mental health
- 16.3 Conclusion
- 16.4 Appendix
- References
- Chapter 17 A look forward to digital therapeutics in 2040 and how clinicians and institutions get there
- 17.1 Introduction
- 17.2 Technology's role in shifting care: market pull from users and the push from artificial intelligence
- 17.3 A look at how users' experience of care and clinical workflow will change by 2040
- 17.4 Using technology for integrating care
- 17.5 System and institutional shifts for 2030–2040
- 17.6 Discussion
- 17.7 Conclusions
- Acknowledgments
- Conflicts of Interest
- References
- Index
- No. of pages: 268
- Language: English
- Edition: 1
- Published: September 27, 2022
- Imprint: Academic Press
- Paperback ISBN: 9780323900454
- eBook ISBN: 9780323885614
NJ
Nicholas C. Jacobson
Nick Jacobson is a tenure-track assistant professor in the departments of Biomedical Data Science and Psychiatry within the Center for Technology and Behavioral Health in the Geisel School of Medicine at Dartmouth College. He directs the AI and Mental Health: Innovation in Technology Guided Healthcare (AIM HIGH) Laboratory.
Dr. Jacobson researches the use of technology to enhance both the assessment and treatment of anxiety and depression. His work has focused on (1) enhancing precision assessment of anxiety and depression using intensive longitudinal data, (2) conducting multimethod assessment utilizing passive sensor data from smartphones and wearable devices, and (3) providing scalable, personalized technology-based treatments utilizing smartphones. He has a strong interest in creating personalized just-in-time adaptive interventions and the quantitative tools that make this work possible. To date, Dr. Jacobson’s smartphone applications which assess and treat anxiety and depression have been downloaded and installed by more than 50,000 people in over 100 countries.
Affiliations and expertise
Tenure-track assistant professor, departments of Biomedical Data Science and Psychiatry within the Center for Technology and Behavioral Health in the Geisel School of Medicine, Dartmouth College, USATK
Tobias Kowatsch
Dr. Tobias Kowatsch is Assistant Professor for Digital Health at the University of St. Gallen and the Scientific Director of the Center for Digital Health Interventions, a joint initiative of the Department of Management, Technology and Economics at ETH Zurich and the Institute of Technology Management at the University of St. Gallen. In close collaboration with his interdisciplinary team and research partners, Tobias designs digital health interventions ("digital pills") at the intersection of information systems reserach, comuter science and behavioral medicine. He helped initiate and participates in the on-going development of MobileCoach, an open source platform for ecological momentary assessments, health monitoring and digital health interventions. He is also co-founder of the ETH Zurich and University of St. Gallen spin-off company Pathmate Technologies that creates and delivers digital clinical pathways.
Affiliations and expertise
Assistant Professor for Digital Health, University of St. Gallen, Switzerland; Scientific Director of the Center for Digital Health Interventions, a joint initiative of the Department of Management, Technology and Economics at ETH Zurich and the Institute of Technology Managemen, University of St. Gallen, SwitzerlandLM
Lisa A. Marsch
Dr. Lisa A. Marsch is the Director of the Dartmouth Center for Technology and Behavioral Health, a designated “Center of Excellence” supported by the National Institute on Drug Abuse at the National Institutes of Health.
She is also the Director of the Northeast Node of the National Drug Abuse Clinical Trials Network based out of Dartmouth and the Andrew G. Wallace Professor within the Department of Psychiatry at the Geisel School of Medicine at Dartmouth College. And, she leads a national “Science of Behavior Change” initiative supported by the National Institutes of Health with partners at Dartmouth, Stanford, Arizona State University, Drexel, and MIT.
In addition to directing this national Center, Dr. Marsch has personally been Principal Investigator on 35 grants, largely from the National Institutes of Health. She has led the development, evaluation and implementation of technology-based therapeutic tools for addiction treatment, HIV prevention, mental health, chronic pain management, substance abuse prevention, smoking cessation, and binge eating disorder. Her work in technology and addiction treatment has been particularly pioneering, as she is widely recognized as having led the development of one of the most widely tested and evidence-based mobile intervention for addiction treatment.
Dr. Marsch publishes extensively and is a regular keynote speaker at national and international scientific meetings (including invited presentations at the White House, Congressional briefings, the World Bank, and for the US Surgeon General). She has served as a consultant to the Department of Mental Health and Substance Abuse at the World Health Organization. She serves on the National Advisory Council to the National Institute on Drug Abuse at the National Institutes of Health. And, she serves on the Health Information Technology Policy Committee on Advanced Health Models and Meaningful Use for the U.S. Office of the National Coordinator.
She also led the development of a seminal book from Oxford University Press on the state of the science of leveraging technologies in transforming behavioral health care.
Affiliations and expertise
Director of the Dartmouth Center for Technology and Behavioral Health, a designated “Center of Excellence” supported by the National Institute on Drug Abuse, National Institutes of Health, LebanonRead Digital Therapeutics for Mental Health and Addiction on ScienceDirect